SCHEMBL5023490

SCHEMBL5023490

CCOc1ccc(Nc2nc3ccccc3s2)cc1OCC

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.57
RAB9A P51151 8/20 0.57
SMN1; SMN2 Q16637 7/20 0.57
KMT2A Q03164 5/20 0.57
MAPT P10636 5/20 0.57
MEN1 O00255 4/20 0.57
POLB P06746 2/20 0.56
NFKB1 P19838 1/20 0.56
NFKB2 Q00653 1/20 0.56
RELA Q04206 1/20 0.56
CASP3 P42574 1/20 0.55
SENP8 Q96LD8 1/20 0.55
SENP7 Q9BQF6 1/20 0.55
SENP6 Q9GZR1 1/20 0.55
SSTR5 P35346 2/20 0.53
ALDH1A1 P00352 3/20 0.51
LMNA P02545 1/20 0.51
HPGD P15428 1/20 0.51
RXFP1 Q9HBX9 1/20 0.49
PIK3CG P48736 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5027153 0.84 NPC1 (0.70) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL29369155 0.83 KMT2A (0.72) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL5022950 0.83 KMT2A (0.72) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL5027286 0.78 NPC1 (0.65) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL5023068 0.77 NPC1 (0.64) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL1820695 0.75 RAB9A (0.70) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL5025801 0.75 NPC1 (0.64) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL12827995 0.74 NPC1 (0.60) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL13595038 0.74 NPC1 (0.50) NPC1RAB9ASMN1; SMN2KMT2AMAPT
SCHEMBL1821678 0.73 NPC1 (1.00) NPC1RAB9ASMN1; SMN2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1638556-B1 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS HOFFMANN LA ROCHE (CH) 2008-04-02 EP disclosed
US-20070021478-A1 Benzothiazolyl derivatives NETTEKOVEN MATTHIAS H 2007-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021478-A1 Benzothiazolyl derivatives CNR1, CNR2, GPR119 NPC1 421/4885RAB9A 1479/4885SMN1; SMN2 3860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.